Date: 2014-09-23
Type of information: Nomination
Compound:
Company: BiogenIdec (USA - MA)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On September 23, 2014, Biogen Idec announced that Olivier Danos, Ph.D., has joined the company as senior vice president, Gene Therapy. Dr. Danos reports directly to Douglas Williams, Ph.D., executive vice president, Research and Development, and is a member of Biogen Idec’s Senior Research and Development Leadership Team. Dr. Danos will lead the company’s gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering. As part of his role, Dr. Danos will also identify potential collaborations that complement the company’s internal capabilities and support the development of treatments across Biogen Idec’s therapeutic focus areas. Dr. Danos joins Biogen Idec from Kadmon Pharmaceuticals, where he served as senior vice president, Molecular Medicine, Synthetic Biology and Gene Regulation since 2011. Prior to Kadmon, Dr. Danos acted as the director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital – Enfants Malades in Paris. Dr. Danos also served as chief scientific officer at Genethon and senior director of research at Somatix Therapy Corporation. He has held several senior roles at the French National Centre for Scientific Research (CNRS) and at the Institut Pasteur in Paris. Dr. Danos is the former president and a founding member of the European Society of Gene and Cell Therapy.
Financial terms:
Latest news:
